Outlook Therapeutics is a biopharmaceutical company focused on ONS-5010/LYTENAVA, the first approved ophthalmic formulation of bevacizumab, authorized by the European Commission (EU) and MHRA (UK) for treating wet age-related macular degeneration (wet AMD) in adults. The company launched directly in Germany and the UK in June 2025 and has a BLA under FDA review for U.S. approval. ONS-5010/LYTENAVA is manufactured in the United States.
expected 2026-12-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-19 | 2025-09-30 | 0001104659-25-123264 | EDGAR | 98K words |
| 2024-12-27 | 2024-09-30 | 0001558370-24-016491 | EDGAR | 94K words |
| 2023-12-22 | 2023-09-30 | 0001558370-23-020000 | EDGAR | 85K words |
| 2022-12-29 | 2022-09-30 | 0001558370-22-019036 | EDGAR | 81K words |
| 2021-12-23 | 2021-09-30 | 0001558370-21-017007 | EDGAR | — |
| 2020-12-23 | 2020-09-30 | 0001558370-20-014540 | EDGAR | — |
| 2019-12-19 | 2019-09-30 | 0001104659-19-074095 | EDGAR | — |
| 2018-12-18 | 2018-09-30 | 0001144204-18-065142 | EDGAR | — |
| 2017-12-29 | 2017-09-30 | 0001571049-17-008779 | EDGAR | — |
| 2016-12-29 | 2016-09-30 | 0001571049-16-020882 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-18 | 2026-06-30 | 0001104659-26-098415 | EDGAR | 30K words |
| 2026-02-17 | 2025-12-31 | 0001104659-26-016554 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011588 | EDGAR | 21K words |
| 2025-05-15 | 2025-03-31 | 0001558370-25-007873 | EDGAR | 28K words |
| 2025-02-14 | 2024-12-31 | 0001558370-25-001022 | EDGAR | 26K words |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012234 | EDGAR | 28K words |
| 2024-05-15 | 2024-03-31 | 0001558370-24-008318 | EDGAR | 27K words |
| 2024-02-14 | 2023-12-31 | 0001558370-24-001172 | EDGAR | 24K words |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014866 | EDGAR | 24K words |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009942 | EDGAR | 23K words |
| 2023-02-14 | 2022-12-31 | 0001558370-23-001286 | EDGAR | 21K words |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013086 | EDGAR | 22K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-18 | 0001104659-26-108952 | EDGAR | 0K words |
| 2026-08-27 | 0001104659-26-102446 | EDGAR | 6K words |
| 2026-08-14 | 0001104659-26-096510 | EDGAR | 24K words |
| 2026-08-14 | 0001104659-26-096478 | EDGAR | 4K words |
| 2026-08-12 | 0001104659-26-094848 | EDGAR | 41K words |
| 2026-07-24 | 0001104659-26-086406 | EDGAR | 1K words |
| 2026-07-24 | 0001104659-26-086685 | EDGAR | 2K words |
| 2026-07-16 | 0001104659-26-084242 | EDGAR | 1K words |
| 2026-03-25 | 0001104659-26-034601 | EDGAR | 21K words |
| 2026-03-16 | 0001104659-26-028103 | EDGAR | 3K words |
265 total filings indexed. 233 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649989 |
| Ticker | OTLK |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.outlooktherapeutics.com |
| Listed | 2016-05-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OTLK (~200 tokens, structured JSON with cryptographic provenance)